Phase 2 N=26 Inhaled Sodium Nitrite on Heart Failure With Preserved Ejection Fraction
Heart Failure
Primary: Change in Pulmonary Capillary Wedge Pressure During Exercise — -1; -4 millimeters of mercury — p=0.002
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=28 Acute Effects of Inorganic Nitrite on Cardiovascular Hemodynamics in Heart Failure With Preserved Ejection Fraction
Heart Disease · Heart Failure With Preserved Ejection Fraction · Exercise Intolerance
Primary: Exercise Pulmonary Capillary Wedge Pressure (PCWP) — 19.0; 28.0 mm Hg — p=0.0003
Phase 2 N=56 Anemia in Heart Failure With a Preserved Ejection Fraction (HFPEF)
Anemia
Primary: Change in Left Ventricular End-diastolic Volume — -6; -4 mL
Phase 4 N=37 Circulating NEP and NEP Inhibition Study in Heart Failure With Preserved Ejection Fraction
Heart Failure With Preserved Ejection Fraction
Primary: Change in Plasma N-terminal Proatrial Natriuretic Peptide (NT proANP) — 47.4; 46.4 pg/mL
Phase 4 N=55 Myocardial Perfusion, Oxidative Metabolism, and Fibrosis in HFpEF
Heart Failure, Diastolic · Diastolic Heart Failure · Hypertension
Primary: Coronary Flow Reserve — 2.64; 2.65; 2.06 ratio
N/A N=100 Exercise Intolerance in Elderly Patients With Diastolic Heart Failure
Heart Failure, Diastolic · Obesity
Primary: Exercise Capacity — 15.5; 15.5; 14.1; 16.6 ml/kg/min — p=<0.001
N/A N=602 Heart Failure Optimization Study
Sudden Cardiac Death · Sudden Cardiac Arrest · Heart Failure
Primary: Percentage of Patients With LVEF Recovery at Day 90 and 180 — 222; 0; 0; 0 Participants
Phase 4 N=90 Diuretics and Dopamine in Heart Failure With Preserved Ejection Fraction
Heart Failure, Diastolic
Primary: Percent Change in Serum Creatinine at 72 Hours. — 4; 11; 5; 20 percent change in serum creatinine
N/A N=335 Heart Failure Study: The Atlanta Cardiomyopathy Consortium
Heart Failure
Primary: Death, Heart Transplant, Left Ventricular Assist Device Implantation — 35 participants
Phase 2 N=15 Oral Nitrite for Older Heart Failure With Preserved Ejection Fraction
Heart Failure
Primary: Cardiorespiratory Fitness — 4.1; 4.0; 5.1; 4.5 ml/kg/min
N/A N=19 High Intensity Interval Exercise in Diastolic Heart Failure
Diastolic Heart Failure
Primary: Left Ventricular Diastolic Dysfunction — 2.1; 2; 1.3; 2.2 DD grade
Phase 2 N=58 Natriuretic Peptide System as Therapy in Human Preclinical Left Ventricle Dysfunction
Congestive Heart Failure
Primary: Change in Natriuresis (Urinary Sodium Excretion) in Control Subjects at 60 Minutes After Volume Expansion Compared to Baseline in Response to Placebo Treatment — 87.19…
Phase 4 N=52 Effects of Aliskiren on Patient With Heart Failure and a Normal Ejection Fraction
Heart Failure
Primary: Exercise Treadmill Time — 621; 580; 624; 579 seconds — p=0.90
Phase 2 N=44 Vasodilator Therapy for Heart Failure and Preserved Ejection Fraction
Heart Failure · Congestive Heart Failure
Primary: Wave Reflection Magnitude — 0.38; 0.44; 0.37 dimensionless ratio
N/A N=349 Impact of Heart Failure Center Program on Cardiac Outcomes in Patients With Heart Failure
Death · Congestive Heart Failure
Primary: All-cause Death, Heart Failure-related Re-hospitalizations, and a Composite Outcome of Both Death and Heart Failure-related Re-hospitalizations — 36; 15; 41; 18…
Phase 2 N=71 Effect of Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Reduced Ejection Fraction
Heart Failure
Primary: Change in Left Ventricular End Systolic Volume (ml) — -4.4; -1.2; -3.8 mL
Phase 2 N=30 Nicotinamide Riboside in Systolic Heart Failure
Heart Failure, Systolic
Primary: Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability) — 3.1; 3.2 events/participant
N/A N=11 Exercise Training in Heart Failure: Changes in Cardiac Structure and Function
Heart Failure
Primary: Change in Left Ventricular Systolic Function. — .82; -1.90 percent LVEF — p=.14
N/A N=52 Neuromodulation to Treat Patients With Heart Failure With Preserved Ejection Fraction
Heart Failure With Normal Ejection Fraction
Primary: E/e' (Early Mitral Inflow Doppler Velocity to the Early Diastolic Mitral Annulus Velocity) — 10.4; 9.9 ratio
N/A N=40 Chronotropic Incompetence in Patients With HFpEF
Heart Failure
Primary: Cardiac Beta-receptor Sensitivity — 0.254; 0.156; 0.365 beats per ng/kg/min ISO
N/A N=101 Heart Function in Patients Assessed for Sleep Apnoea
Heart Failure With Preserved Ejection Fraction · Sleep Disordered Breathing · Heart Failure With Normal Ejection Fraction
Primary: Number of Participants With Unrecognised Heart Failure With Preserved Ejection Fraction (HFpEF) in Cohort With Clinically Suspected Sleep Disordered Breathing (SDB) — 7…
Phase 3 N=52 Sildenafil in HFpEF (Heart Failure With Preserved Ejection Fraction) and PH
Heart Failure, Diastolic · Pulmonary Hypertension
Primary: Mean Pulmonary Artery Pressure Measured by Right Heart Catheterization — -2.4; -4.7 mmHG
Phase 2 N=31 Interleukin-1 Blockade in HF With Preserved EF
Heart Failure With Normal Ejection Fraction
Primary: Change in Aerobic Exercise Capacity — -0.2; 1.0 ml/kg/min
N/A N=10 The Effects of Ranolazine on Exercise Capacity in Patients With Heart Failure With Preserved Ejection Fraction
Heart Failure With Preserved Ejection Fraction
Primary: Change in Exercise Capacity at 6 Weeks — 659.9; 300.5 seconds — p=0.47
Early Phase 1 N=13 Treatment of HFpEF With Nitrate Supplement
Heart Failure With Normal Ejection Fraction
Primary: Time on Treadmill — 402.8; 181.2 seconds
Phase 2 N=142 A Study to Evaluate Whether Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease
Heart Failure With Preserved Ejection Fraction
Primary: Percent of Baseline N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) Assessed at Week 24 — 108.39; 106.27 percentage of baseline NT-proBNP — p=0.7923
Phase 3 N=504 DETERMINE-preserved - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Preserved Ejection Fraction
Heart Failure With Preserved Ejection Fraction (HFpEF)
Primary: Change From Baseline in Kansas-City Cardiomyopathy Questionnaire-Total Symptom Score (KCCQ-TSS) at Week 16 (Higher Scores Represent Less HF Symptom Frequency and Burden)…
Phase 2 N=35 Heart Failure Polypill at a Safety Net Hospital
Heart Failure With Reduced Ejection Fraction · HIV Infections
Primary: Measured Adherence to GDMT by Pill Count — 74.6; 83.3 adherence ratio expressed in %
Phase 2 N=24 Oral Nitrite in Patients With Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction
Pulmonary Hypertension Secondary · Heart Failure
Primary: Mean Pulmonary Artery Pressure (mPAP) During Submaximal Exercise as Compared Between Placebo and Nitrite — 48.75; 48.68; 56.81; 55.0 mmHg — p=0.20
Phase 3 N=2,572 A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients
Heart Failure With Preserved Ejection Fraction
Primary: Change From Baseline in N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) at Week 12 — 0.8218; 0.9828 Ratio — p=<0.0001